Genzyme Tops Cobrek In Kidney Drug Patent Fight

Law360, Los Angeles (March 22, 2012, 9:08 PM EDT) -- An Illinois federal judge ruled Thursday that a Genzyme Corp. patent covering kidney disease treatment Hectorol is valid and enforceable in the drugmaker's suit against Cobrek Pharmaceuticals Inc. over a generic version of a renal drug that Cobrek had conceded infringing.

U.S. District Judge Robert M. Dow Jr. rejected defense arguments that the claimed invention — use of active ingredient doxercalciferol to treat end stage renal disease — was obvious in 1988, when a related patent was filed.

“As of 1988, no one had treated human...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.